Fig. 1: Lysosomal EGFR is crucial for mTORC1 activation.
From: Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1
a, b Quantification of the p-T389-S6K1/S6K1 (a) and p-S473-AKT/AKT (b) ratios in NSCLC patients tested by IHC. Data are presented as means ± SD. Two-tailed unpaired t-test. c Afatinib causes much stronger inhibition of mTORC1 activation than erlotinib, although both are capable of suppressing EGFR tyrosine kinase activity. PC9 and HCC827 cells were treated with erlotinib or afatinib at the indicated dose for 12 h and analyzed by western blotting. d LY3000328 or Dyngo-4a impairs the activation of mTORC1 in cells harboring mutant EGFR. PC9, HCC827, or NCI-H1975 cells were treated with DMSO, 50 μM LY3000328 for 24 h, or 50 μM Dyngo-4a for 2 h, and analyzed by western blotting.
